Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › sugammadex

sugammadex

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of sugammadex

67 trials tracked of sugammadex: 56 in phase 3 or 4 and 22 with published results. The most-cited published study has 374 citations.

67Trials tracked
56Phase 3 & 4
0Recruiting
22With published results
Phase distribution
Phase 4 33 Phase 3 23 Phase 2 6 Phase 1 2 Other / NA 3
  1. Phase 3 Comparison of Sugammadex (MK-8616/Org 25969) With Neostigmine Administered at 1-2 Post-tetanic Counts (PTCs) After Administration of Rocuronium or Vecuronium (19.4.302/P05945/MK-8616-025) Completed · 374 cited
  2. Phase 4 Neuromuscular Blockade During Transurethral Resection of Bladder Cancer Completed · 257 cited
  3. Phase 3 Comparison of Recovery From Rocuronium 1.2 mg/kg Followed by Sugammadex (Org 25969) 16 mg/kg at 3 Minutes With Recovery From Succinylcholine 1.0 mg/kg (19.4.303)(P05946)(MK-8616-026) Completed · 242 cited
  4. Phase 3 Comparison of Sugammadex (Org 25969) With Neostigmine as Reversal Agents for Rocuronium or Vecuronium at Reappearance of T2 (P05960) Completed · 237 cited
  5. Phase 4 The Effect of Sugammadex Versus Neostigmine on Postoperative Pulmonary Complications Completed · 148 cited
  6. Phase 3 Comparison of the Efficacy, Safety, and Pharmacokinetics of Sugammadex (MK-8616; Org 25969) in Elderly Participants With Adult Participants (MK-8616-029) Completed · 120 cited
Show 44 more trials
  1. Phase 3 Evaluating Outcomes in Cardiac Surgery Patients Who Receive Sugammadex vs. Placebo Completed · 67 cited
  2. Phase 3 Safety and Efficacy of Sugammadex (Org 25969, MK-8616) in Participants With or Having a Past History of Pulmonary Disease (19.4.308) (P05932) (MK-8616-017) Completed · 55 cited
  3. Phase 3 Sugammadex After Continuous Infusion of Rocuronium During Sevoflurane and Propofol Anesthesia (P05949; MK-8616-028) Completed · 54 cited
  4. Phase 4 Neuromuscular Blockade on Shoulder Pain of Elderly Completed · 28 cited
  5. Phase 4 Deep Neuromuscular Block for Laparoscopic Surgery Completed · 23 cited
  6. Phase 4 Quality of Recovery After Reversal With Neostigmine or Sugammadex. Completed · 18 cited
  7. Phase 4 Speed of Recovery of Reversal of Neuromuscular Blockade in Geriatric Patients Undergoing Spine Surgery Completed · 17 cited
  8. Phase 4 Sugammadex Versus Neostigmine for Reversal of Rocuronium Neuromuscular Completed · 12 cited
  9. Phase 3 Compare the Oncological Benefit of Deep Neuromuscular Block in Gastric Cancer Obesity Patient Completed · 8 cited
  10. Phase 4 Sugammadex To IMprove Bowel Function Completed · 3 cited
  11. Phase 4 Designing Optimal Prevention and Management of Postoperative Nausea and Emesis for Patients Undergoing Laparoscopic Sleeve Gastrectomy Completed · 2 cited
  12. Phase 3 Use of Sugammadex at the End of Case in Routine Anesthesia (MK-8616-023) Completed · 2 cited
  13. Phase 4 Muscle Relaxation for Pediatric Adenotonsillectomy Completed
  14. Phase 4 Role of Sugammadex as Reversal Agent in Patients Extubated Immediately After Isolated Coronary Artery Bypass Grafting Surgery Completed
  15. Phase 4 Postoperative Urinary Retention After Reversal of Neuromuscular Block by Neostigmine Versus Sugammadex Completed
  16. Phase 4 Sugammadex Versus Neostigmine for Reversal of Neuromuscular Blockade at the End of Kidney Transplantation Surgery Completed
  17. Phase 4 Effect of Neuromuscular Reversal With Sugammadex on Postoperative Recovery Profile Completed
  18. Phase 4 The Effect of Deep Neuromuscular Block on Surgical Condition During Laparoscopic Colorectal Surgery Completed
  19. Phase 4 Study to Determine if Administration of Sugammadex Impacts Hospital Efficiency Completed
  20. Phase 4 Investigation of Sugammadex in Outpatient Urological Procedures Completed
  21. Phase 4 Can Adequacy of Anesthesia Depth and Quality of Recovery be Influenced by the Level of Neuromuscular Blockade? Completed
  22. Phase 4 Deep vs Moderate Neuromuscular Blockade With Rocuronium in Patients Undergoing Endolaryngeal Procedures Completed
  23. Phase 4 Effect of Neuromuscular Blockade and Reversal on Breathing Completed
  24. Phase 4 Sugammadex vs. Neostigmine for Neuromuscular Blockade Reversal in Thoracic Surgical Patients Completed
  25. Phase 4 Sugammadex and Decreased Time to Extubation Completed
  26. Phase 4 Sugammadex vs Placebo to Prevent Residual Neuromuscular Block Completed
  27. Phase 4 Optimizing Post-operative Recovery in Bariatric Patients With Obstructive Sleep Apnea Undergoing Outpatient Surgery: A Comparison of Sugammadex and Neostigmine Completed
  28. Phase 4 Comparison of Time to Extubation Using Sugammadex or Neostigmine Completed
  29. Phase 4 Postoperative Urinary Retention in Patients After Noncardiac Surgery and Reversal of Neuromuscular Block Completed
  30. Phase 4 Impact of Sugammadex vs. Neostigmine Reversal on Post-Operative Recovery and Complications Completed
  31. Phase 4 Use of Sugammadex for Reversal of Paralysis in Microlaryngoscopy Completed
  32. Phase 4 Sugammadex as Rescue Therapy Completed
  33. Phase 4 Optimizing Surgical Conditions During Gynecologic Laparoscopic Surgery With Deep Neuromuscular Blockade Completed
  34. Phase 4 Influence of Mild Hypothermia on Reversal of Rocuronium With Sugammadex Completed
  35. Phase 4 A Study Comparing the Use of Deep or Standard Neuromuscular Blockade in Combination With Low or Standard Insufflation Pressures in Participants Undergoing Laparoscopic Cholecystectomy (P07982) Completed
  36. Phase 4 Effects of Magnesium Sulphate on Sugammadex Reversal of Rocuronium Induced Blockade in Gynaecology Patients Completed
  37. Phase 3 Study of Recovery of Strength After Surgery Comparing Two Different Medications for Reversal of Muscle Relaxant Completed
  38. Phase 3 The POUR (Postoperative Urinary Retention) Study Completed
  39. Phase 3 Study of Sugammadex Versus Usual Care on Incidence of Residual Blockade at Post Anesthesia Care Unit Admission (P07981) Completed
  40. Phase 3 Reversal of Neuromuscular Blockade With Sugammadex or Usual Care in Hip Fracture Surgery or Joint (Hip/Knee) Replacement (P07038) Completed
  41. Phase 3 Dialysis of Sugammadex in Participants With Severe Renal Impairment (Study 19.4.333) (P05773) Completed
  42. Phase 3 Comparing 4.0 mg.Kg-1 Sugammadex With Placebo in the Reversal of Profound Neuromuscular Blockade (P05767) Completed
  43. Phase 3 Comparison of Sugammadex Administered at 1-2 Post Tetanic Counts (PTCs) or Better With Neostigmine Administered as Per Standard of Care to Reverse Rocuronium-Induced Neuromuscular Blockade in Adults Undergoing Elective Open Abdominal Procedure (19.4.334) (P05774) Completed
  44. Phase 3 Comparison of Sugammadex With Neostigmine as Reversal Agents for Rocuronium at Reappearance of T2 (Study P06101) Completed

Showing the 50 most-cited and recently-updated of 67 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
General anesthesia with reduced rocuronium and sugammadex reversal safely enabled cesarean section in a patient with inclusion body myositis
Anesthesiology & Pain Medicine Sys. Review
General anesthesia with reduced rocuronium and sugammadex reversal safely enabled cesarean section in a patient with inclusion body myositis A single case shows safe anesthesia for a pregnant patient with inclusion body myositis
This case report describes the perioperative anesthetic management of a 43-year-old pregnant patient with inclusion body myositis undergoing…
A 43-year-old pregnant patient with inclusion body myositis had a cesarean section without complications. Her baby scored 10 out of 10 on Ap…
Frontiers Jun 2, 2026
Sugammadex improves diaphragmatic excursion and reduces pulmonary complications in morbidly obese patients
Diabetes & Endocrinology RCT
Sugammadex improves diaphragmatic excursion and reduces pulmonary complications in morbidly obese patients Sugammadex Helps Obese Patients Breathe Easier
A randomized double-blind controlled trial in 104 morbidly obese patients compared sugammadex (2 mg/kg) with neostigmine+atropine.
This new research shows that a specific reversal drug helps morbidly obese patients breathe better and avoid lung issues after surgery.
Apr 14, 2026